CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Subscribe To Our Newsletter & Stay Updated